Chemotherapy for Advanced Gastric Cancer
Author Information
Author(s): Kim S T, Kang W K, Kang J H, Park K W, Lee J, Lee S-H, Park J O, Kim K, Kim W S, Jung C W, Park Y S, Im Y-H, Park K
Primary Institution: Samsung Medical Center, Sungkyunkwan University School of Medicine
Hypothesis
Can a combination of irinotecan, 5-fluorouracil, and leucovorin effectively treat metastatic gastric cancer patients who have previously failed taxane and cisplatin treatment?
Conclusion
The combination of irinotecan, 5-FU, and leucovorin showed moderate activity and a favorable toxicity profile as a second-line treatment in metastatic gastric cancer patients.
Supporting Evidence
- The overall response rate was 21% among assessable patients.
- The median time to progression was 2.5 months.
- The median overall survival was 7.6 months.
Takeaway
Doctors tested a new medicine mix to help people with stomach cancer that didn't get better with other treatments, and it worked a little bit.
Methodology
Patients received irinotecan, leucovorin, and 5-FU every two weeks until disease progression.
Limitations
The study was limited by the small sample size and the lack of a control group.
Participant Demographics
The median age of participants was 55 years, with 73% male and all having metastatic disease.
Statistical Information
Confidence Interval
95% CI, 10–32%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website